Geron Corporation (GERN) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.65
• Market Cap: $1.10B
• EPS: $-0.12
• 52-Week High: $2.01
• 52-Week Low: $1.04

Market Sentiment

Geron Corporation currently has a Neutral sentiment score of 0.14.

About Geron Corporation

Geron Corporation is a clinical biopharmaceutical company headquartered in Foster City, California, specializing in the development and commercialization of innovative therapies for myeloid hematologic neoplasms, particularly acalabrutinib and telomerase inhibitors. With a robust pipeline and a commitment to addressing unmet medical needs in this field, Geron aims to transform the treatment landscape for patients with blood cancers. The company is positioned at the forefront of hematology res...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Geron Corporation and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does GERN pay dividends?

Geron Corporation (GERN) does not currently pay a regular dividend.

What is GERN's market cap?

Geron Corporation (GERN) has a market capitalization of $1.10B with a current stock price of $1.65.